Formulation design, preparation and physicochemical characterizations of solid lipid nanoparticles containing a hydrophobic drug: effects of process variables

This study aimed to prepare solid lipid nanoparticles (SLNs) of a hydrophobic drug, tretinoin, by emulsification-ultrasonication method. Solubility of tretinoin in the solid lipids was examined. Effects of process variables were investigated on particle size, polydispersity index (PI), zeta potential (ZP), drug encapsulation efficiency (EE), and drug loading (L) of the SLNs. Shape and surface morphology of the SLNs were investigated by cryogenic field emission scanning electron microscopy (cryo-FESEM). Complete encapsulation of drug in the nanoparticles was checked by cross-polarized light microscopy and differential scanning calorimetry (DSC). Crystallinity of the formulation was analyzed by DSC and powder X-ray diffraction (PXRD). In addition, drug release and stability studies were also performed. The results indicated that 10mg tretinoin was soluble in 0.45±0.07 g Precirol? ATO5 and 0.36±0.06 g Compritol? 888ATO, respectively. Process variables exhibited significant influence in producing SLNs. SLNs with <120 nm size, <0.2 PI, >I30I mV ZP, >75% EE, and ～0.8% L can be produced following the appropriate formulation conditions. Cryo-FESEM study showed spherical particles with smooth surface. Cross-polarized light microscopy study revealed that drug crystals in the external aqueous phase were absent when the SLNs were prepared at ≤0.05% drug concentration. DSC and PXRD studies indicated complete drug encapsulation within the nanoparticle matrix as amorphous form. The drug release study demonstrated sustained/prolonged drug release from the SLNs. Furthermore, tretinoin-loaded SLNs were stable for 3 months at 4°C. Hence, the developed SLNs can be used as drug carrier for sustained/prolonged drug release and/or to improve oral absorption/bioavailability.     

Polyethyleneimine/poly-(γ-glutamic acid)/poly(lactide-co-glycolide) nanoparticles for loading and releasing antiretroviral drug

Nanoparticles (NPs) with ternary components of polyethyleneimine (PEI), poly-(γ-glutamic acid) (γ-PGA), and poly(lactide-co-glycolide) (PLGA) were applied to carry and release saquinavir (SQV). Hydrophobic SQV was encapsulated in the particle core composed of PLGA to form SQV-PLGA NPs, and the surface of SQV-PLGA NPs was grafted successively with hydrophilic γ-PGA and PEI (PEI/γ-PGA/SQV-PLGA NPs). The morphological images revealed that PEI/γ-PGA/SQV-PLGA NPs were spheroid-like, in general. An increase in the concentration of didecyl dimethylammonium bromide and a reduction in the dose of SQV enhanced the entrapment efficiency of SQV in PLGA NPs. In addition, an increment in the molecular weight of γ-PGA reduced the grafting efficiency of PEI on γ-PGA/SQV-PLGA NPs. An increase in the weight percentage of PEI enhanced the average particle diameter. However, the grafting efficiency of PEI on γ-PGA/SQV-PLGA NPs and the dissolution rate of SQV from PEI/γ-PGA/SQV-PLGA NPs reduced when the weight percentage of PEI increased. PEI/γ-PGA/SQV-PLGA NPs are an innovative drug delivery system and can be used for antiretroviral trials.     

Central Composite Design for Formulation and Optimization of Solid Lipid Nanoparticles to Enhance Oral Bioavailability of Acyclovir

Treatment of herpes simplex infection requires high and frequent doses of oral acyclovir to attain its maximum therapeutic effect. The current therapeutic regimen of acyclovir is known to cause unwarranted dose-related adverse effects, including acute kidney injury. For this reason, a suitable delivery system for acyclovir was developed to improve the pharmacokinetic limitations and ultimately administer the drug at a lower dose and/or less frequently. In this study, solid lipid nanoparticles were designed to improve the oral bioavailability of acyclovir. The central composite design was applied to investigate the influence of the materials on the physicochemical properties of the solid lipid nanoparticles, and the optimized formulation was further characterized. Solid lipid nanoparticles formulated from Compritol 888 ATO resulted in a particle size of 108.67 ± 1.03 nm with an entrapment efficiency of 91.05 ± 0.75%. The analyses showed that the optimum combination of surfactant and solid lipid produced solid lipid nanoparticles of good quality with controlled release property and was stable at refrigerated and room temperature for at least 3 months. A five-fold increase in oral bioavailability of acyclovir-loaded solid lipid nanoparticles was observed in rats compared to commercial acyclovir suspension. This study has presented promising results that solid lipid nanoparticles could potentially be used as an oral drug delivery vehicle for acyclovir due to their excellent properties.     

Thermal characterization and compatibility studies of itraconazole and excipients for development of solid lipid nanoparticles

The current study was performed to investigate possible interactions between triazole antifungal drug itraconazole (ITR) with selected excipients commonly used for development of solid lipid nanoparticles. The excipients included common lipids (glyceryl behenate (Compritol 888 ATO?), glyceryl monostearate, stearic acid, and cetyl palmitate), charge inducers (dicetyl phosphate and stearlyamine), and surfactants (sodium cholate and sodium deoxycholate). Differential scanning calorimetry, isothermal stress testing, Fourier transform infrared spectral analysis, optical microcopy, and X-ray powder diffraction analysis were performed for assessing the compatibility between the drug and the excipients. Results of the study suggest that the stearic acid exhibited drug–excipient interactions, whereas all other excipients used in the study were found to be compatible with ITR.     

Ciprofloxacin Loaded Alginate/Chitosan and Solid Lipid Nanoparticles,Preparation, and Characterization

The aim of the present study was to develop controlled drug delivery systems based on nanotechnology. Two different nanocarriers were selected, chitosan-alginate nanoparticles as hydrophilic and solid lipid nanoparticles as lipophilic carriers. Nanoparticles were prepared and characterized by evaluating particle size, zeta potential, SEM pictures, DSC thermograms, percentage of drug loading efficiency, and drug release profile. The particle size of SLNs and Chi/Alg nanoparticles was 291 ± 5 and 520 ± 16. Drug loading efficiency of Chi/Alg and SLN particles were 68.98 ± 5.5% and 88 ± 4.5%. The drug release was sustained with chitosan-alginate system for about 45 hours whereas for SLNs >98% of the drug was released in 2 hours. Release profile did not change significantly after freeze drying of particles using cryoprotector. Results suggest that under in vitro condition chitosan/alginate systems can act as promising carriers for ciprofloxacin and may be used as an alternative system in sustained delivery of ciprofloxacin.     

Cyclodextrin Complexed Lipid Nanoparticles of Irbesartan for Oral Applications: Design,Development, and In Vitro Characterization

Irbesartan (IR) is an angiotensin II receptor antagonist drug with antihypertensive activity. IR bioavailability is limited due to poor solubility and first-pass metabolism. The current investigation aimed to design, develop, and characterize the cyclodextrin(s) (CD) complexed IR (IR-CD) loaded solid lipid nanoparticles (IR-CD-SLNs) for enhanced solubility, sustained release behavior, and subsequently improved bioavailability through oral administration. Based on phase solubility studies, solid complexes were prepared by the coacervation followed by lyophilization method and characterized for drug content, inclusion efficiency, solubility, and in vitro dissolution. IR-CD inclusion complexes demonstrated enhancement of solubility and dissolution rate of IR. However, the dissolution efficiency was significantly increased with hydroxypropyl-βCD (HP-βCD) inclusion complex than beta-CD (βCD). SLNs were obtained by hot homogenization coupled with the ultrasonication method with IR/HP-βCD inclusion complex loaded into Dynasan 112 and glycerol monostearate (GMS). SLNs were evaluated for physicochemical characteristics, in vitro release, differential scanning calorimetry (DSC), powder X-ray diffractometry (PXRD), and physical stability at room temperature for two months. The optimized SLNs formulation showed particle size, polydispersity index, zeta potential, assay, and entrapment efficiency of 257.6 ± 5.1 nm, 0.21 ± 0.03, −30.5 ± 4.1 mV, 99.8 ± 2.5, and 93.7 ± 2.5%, respectively. IR-CD-SLN and IR-SLN dispersions showed sustained release of IR compared to the IR-CD inclusion complexes. DSC results complimented PXRD results by the absence of IR endothermic peak. Optimized IR-CD complex, IR-SLN, and IR-CD-SLN formulations were stable for two months at room temperature. Thus, the current IR oral formulation may exhibit improved oral bioavailability and prolonged antihypertensive activity, which may improve therapeutic outcomes in the treatment of hypertension and heart failure.     

Optimization and validation of stability indicating RP-HPLC method for the quantification of gefitinib in bulk drug and nanoformulations: An application towards in vitro and ex vivo performance evaluation

Gefitinib (GFB) is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used primarily to treat non-small cell lung cancer (NSCLC), but it also works by lowering AKT and MAPK phosphorylation, which makes it effective against the breast cancer cells. A high-performance liquid chromatography (HPLC) method was developed for detecting gefitinib by C18 analytical column with mobile phase containing acetonitrile and 1 % w/v ammonium acetate in water with ratio of 60:40. Box-Behnken design was used to optimize the chromatographic conditions, and method was validated for accuracy, precision, linearity, robustness, ruggedness, limit of detection, and limit of quantification. The developed method was found to be useful in estimating gefitinib in conventional marketed tablet dosage forms and nanoformulations such as SLNs and liposomes. With a calibration curve, linearity was attained in the drug concentration range of 8–56 µg/mL (r² = 0.9996), and sensitivity was found to be 1.3 and 3.9 µg/mLas LOD and LOQ, respectively. All the validation criteria for the method were within the acceptable limits. The drug content in the conventional tablet formulation was found to be 99.99 %. The HPLC analysis indicated that gefitinib was highly soluble in Precirol ATO5 as solid lipid and tween 80 as surfactant. Drug entrapment efficiency was found to be 83.1 % and 80.5 % for SLNs and liposomes respectively. In vitro release data revealed that 30 % of drug was released from plain suspension and more than 77 % released from both nanoformulations after 24 h at pH 7.4 respectively. By applying kinetic fit, data was most appropriately fitted into first order as compared to other. The apparent permeability of gefitinib from plain suspension, SLNs and Liposomes was found to be 3.98 × 10^?4 cm/min, 1.35 × 10^?4 cm/min and 1.79 × 10^?4 cm/min.     

Aripiprazole Loaded Polymeric Biodegradable Microspheres: Formulation and In Vitro Characterization

In the present study, we attempted to prepare biodegradable microspheres of polylactic acid containing aripiprazole in order to achieve its controlled release profile suitable for parenteral administration. Biodegradable microspheres were prepared by solvent evaporation method using methylene dichloride as a solvent. The optimization of various formulation variables (e.g., stirring speed, and polymer:drug ratio, stabilizer concentration) to obtain spherical particles was also investigated. The optimized product was further characterized for various in vitro attributes, such as particle size and its distribution, encapsulation efficiency, surface properties, percentage yield, and in vitro release. Changing the ratio of polymer, stabilizers, and leaching agent (sodium chloride) affected the entrapment efficiency and release rate of aripiprazole. The release quantum was 88.41% when stirring rate was 2000 rpm and it was further increased to 94.65% when stirring speed was increased to 3000 rpm (Formulation E). Drug entrapment of microspheres was increased by increasing the concentration of PVP and maximum entrapment (62.35%) was obtained at 4% concentration of PVP (Formulation E). Spherical particles with good surface characteristics were obtained at stirring rate 3000 rpm and drug:polymer ratio 1:10.     

可生物降解固体脂质纳米粒的制备、表征及药物的体外释放

以可生物降解材料硬脂酸为载体, 以葛根总黄酮为模型药物, 采用乳化蒸发-低温固化法制备固体脂质纳米粒. 采用透射电镜研究载药纳米粒形态, 激光粒度分析仪测定其粒径, X射线衍射仪进行物相鉴别, 并对纳米粒的包封率及体外释药特性等进行了研究. 分析结果表明, 所制备硬脂酸固态脂质纳米粒为类球实体, 粒径分布比较均匀, 平均粒径为(263.82±3.6) nm, 包封率为(67.53±0.12)%. X射线衍射分析证明药物以分子或细小粒子分散于脂质骨架中. 体外释药研究结果表明, 纳米粒体外释药先快后慢, 12 h累积释药50%, 包封于降解材料骨架内的药物通过骨架溶蚀缓慢释放. 药物的体外释放符合Higuchi方程.     

β-Elemene-loaded polymeric micelles intensify anti-carcinoma efficacy and alleviate side effects

β-Elemene is a volatile oil used for the treatment of cancer,but poor solubility,low bioavailability,and various adverse reactions limit its application.For amelio rating risks of the venous toxicity ofβ-elemene,intravenously injectable micelle ofβ-elemene was prepared using the thin-film hydration method.The results pointed out the micelles were uniformly spherical with about 20.96±0.1966 nm in average diameter and exhibited high entrapment efficiency(99.02%±0.88%).As revealed by drug release studies in vitro,β-elemene micelles had sustained drug release.Compared with freeβ-elemene,the micelles increased the drug cellular uptake and enhanced the anti-tumor effect in vitro through retarding cell cycle and inducing apoptosis.Meanwhile,the elevated se rum stability o fβ-elemene micelles implied less drug leakage and reduced toxicity.The wound healing and tube formation assay in vitro demonstrated the anti-metastasis and anti-angiogenesis effects ofβ-elemene micelles.Moreover,the pharmacokinetics study showed the AUC and T1/2 ofβ-elemene in micelle group were 1.79 and 1.62 times of that in free fi-elemene group,suggesting the circulation time ofβ-elemene in the blood had been prolonged.In addition,β-elemene micelles showed a favorable antitumor response compared with theβ-elemene solution on C26 colon cance r-bearing mice model.Local irritation study investigated in rabbits indicated that theβ-elemene micelles strikingly mitigated the irritation to the injection sites compared with freeβ-elemene.These results proved that the micelle could be a good candidate as an auspicious drug delivery system ofβ-elemene for the prospective clinical treatment of carcinoma.     

Preparation,Characterization, and In Vitro Release of Chloramphenicol Loaded Solid Lipid Nanoparticles

In the present contribution, solid lipid nanoparticles have been prepared from oil-in-water microemulsion, using various monoglycerides (monocaprate, monolaurate and monomyristin) as solid matrix, polyethylene glycol sorbitan monooleate (Tween 80) as emulsifier, and chloramphenicol as target drug. The morphology and microstructure of drug loaded SLNs were investigated by use of the transmission electron microscope (TEM) and x-ray diffraction (XRD) techniques. The pictures of TEM showed that SLNs are spherical particles, and the average diameters measured by dynamic light scattering (DLS) were under 100 nm. The crystallographic properties of them were characterized by XRD. It was found that chloramphenicol do not exist in crystalline state in SLN. Both drug-free and drug-loaded SLN existed in amorphous state. In addition, zeta potentials of SLNs were investigated. Zeta potentials of all the samples were around ?6 to ?23 mv. Further more, the core-shell model with drug enriched shell was proposed for the present system. Release kinetics of chloramphenicol from SLN showed a relative fast release in the initial several hours, and the release profile was accordance with the drug incorporation model we presented. Effects of types and concentration of lipids, and surface modifiers on drug release behavior were studied.     

Tryptanthrin-loaded nanoparticles for delivery into cultured human breast cancer cells, MCF7: the effects of solid lipid/liquid lipid ratios in the inner core

Tryptanthrin is an ancient medicine which recently was also found to have a function of downregulating multidrug resistance (MDR). However, tryptanthrin is insoluble in water, which limits its availability for delivery into cancer cells. There is a need to improve delivery systems to increase the inhibition of MDR. The aim of this study was to employ nanoparticles encapsulating tryptanthrin to improve the delivery and promote the sustained release of this drug. The approach was to encapsulate tryptanthrin in various nanoparticles, including solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), and lipid emulsions (LEs). We compared the particle size and zeta potential of these nanoparticles, and evaluated the partitioning behavior of tryptanthrin in them. We also determined the release kinetics of tryptanthrin from these nanoparticles. Moreover, cellular cytotoxicity toward and uptake of tryptanthrin-loaded nanoparticles by human breast cancer cells were determined. We found that the mean particle size of NLCs was lower, and the partition coefficient was higher than those of SLNs, and an increased tryptanthrin release rate was found with the NLC delivery system. NLCs achieved the sustained release of tryptanthrin without an initial burst. In particular, the NLC-C formulation, composed of a mixture of Compritol and squalene as the core materials, showed the highest release rate and cytotoxic effect. Confocal laser scanning microscopic images confirmed drug internalization into cells which enhanced the endocytosis of the particles. These results suggested that NLCs can potentially be exploited as a drug carrier for topical or intravenous use in the future.     

柔性透明自支撑氧化锡锑电纺纳米纤维膜的制备与表征

以四氯化锡和三氯化锑为前驱体,通过静电纺丝技术制备了柔性透明的自支撑氧化锡锑(ATO)纳米纤维膜.研究结果表明,该柔性ATO纤维膜具有四方相金红石晶体结构,且呈无规的纤维网状分布.当前驱体煅烧温度分别为520℃和700℃时,纤维的平均直径为200和150 nm;组成纤维的颗粒的平均粒径为10和19 nm;可见光透过率为72%和80%;电阻率为5.23和2.20Ω·cm.该自支撑ATO纳米纤维膜还显示出优异的柔韧性,在弯曲500次后其电阻率基本不变.     

Preparation,optimization by 2<Superscript>3</Superscript> factorial design,characterization and in vitro release kinetics of lorazepam loaded PLGA nanoparticles

The aim of this work was to formulate the lorazepam loaded poly(lactic-co-glycolic) acid (PLGA) nanoparticles by optimization of different preparation variables using 2³ factorial design. The effect of three independent factors, the amount of polymer, concentration of the stabilizer and volume of organic solvent was investigated on two dependent responses, i.e., particle size and % drug entrapment efficiency. By using PLGA as polymer, PVA as a stabilizer and dimethyl sulfoxide as organic solvent lorazepam loaded PLGA nanoparticles were successfully developed through modified nanoprecipitation method. FTIR and DSC studies were carried out to examine the interaction between the excipients used and to explore the nature of the drug, the formulation and the nature of drug in the formulations. These nanoparticles were characterized for particle size, shape, zeta potential, % drug entrapment efficiency, % process yield and in vitro drug release behavior. In vitro evaluation showed particles size between 161.0 ± 5.4 and 231.9 ± 4.9 nm, % drug entrapment efficiency of formulations was in the range of 60.43 ± 5.8 to 75.40 ± 1.5, % process yield at 68.34 ± 2.3 to 81.55 ± 1.3 was achieved and in vitro drug release for these formulations was in the range of 49.2 to 54.6%. Different kinetics models, such as zero order, first order, Higuchi model, Hixson-Crowell model and Korsmeyer- Peppas model were used to analyze the in vitro drug release data. Preferred formulation showed particle size of 161.0 ± 5.4 nm, PDI as 0.367 ± 0.014,–25.2 mV zeta potential, drug entrapment efficiency as 64.58 ± 3.6% and 72.48 ± 2.5% process yield. TEM results showed that these nanoparticles were spherical in shape, and follow the Korsmeyer-Peppas model with a release exponent value of n = 0.658.     

Fabrication and Biological Assessment of Antidiabetic α-Mangostin Loaded Nanosponges: In Vitro,In Vivo,and In Silico Studies

Type 2 diabetes mellitus has been a major health issue with increasing morbidity and mortality due to macrovascular and microvascular complications. The urgent need for improved methods to control hyperglycemic complications reiterates the development of innovative preventive and therapeutic treatment strategies. In this perspective, xanthone compounds in the pericarp of the mangosteen fruit, especially α-mangostin (MGN), have been recognized to restore damaged pancreatic β-cells for optimal insulin release. Therefore, taking advantage of the robust use of nanotechnology for targeted drug delivery, we herein report the preparation of MGN loaded nanosponges for anti-diabetic therapeutic applications. The nanosponges were prepared by quasi-emulsion solvent evaporation method. Physico-chemical characterization of formulated nanosponges with satisfactory outcomes was performed with Fourier transform infra-red (FTIR) spectroscopy, differential scanning calorimetry (DSC), and scanning electron microscopy (SEM). Zeta potential, hydrodynamic diameter, entrapment efficiency, drug release properties, and stability studies at stress conditions were also tested. Molecular docking analysis revealed significant interactions of α-glucosidase and MGN in a protein-ligand complex. The maximum inhibition by nanosponges against α-glucosidase was observed to be 0.9352 ± 0.0856 µM, 3.11-fold higher than acarbose. In vivo studies were conducted on diabetic rats and plasma glucose levels were estimated by HPLC. Collectively, our findings suggest that MGN-loaded nanosponges may be beneficial in the treatment of diabetes since they prolong the antidiabetic response in plasma and improve patient compliance by slowly releasing MGN and requiring less frequent doses, respectively.     

Catanionic solid lipid nanoparticles carrying doxorubicin for inhibiting the growth of U87MG cells

Catanionic solid lipid nanoparticles (CASLNs), loaded with doxorubicin (Dox) and grafted with anti-epithelial growth factor receptor (EGFR) (anti-EGFR/Dox-CASLNs), were applied to suppressing propagation of malignant U87MG cells. U87MG cells were cultured with anti-EGFR/Dox-CASLNs for assessing the cell viability and EGFR expression. When the concentration of catanionic surfactants, containing hexadecyltrimethylammonium bromide and sodium anionic sodium dodecylsulfate, was 1mM, CASLNs entrapped the largest quantity of Dox. The order of cacao butter (CB) in the entrapment efficiency of Dox was 50% CB>0% CB>100% CB. In addition, the release rate of Dox and the antiproliferative effect on U87MG cells were in the following order: 100% CB>0% CB>50% CB. A high level of CB in anti-EGFR/Dox-CASLNs reduced the cytotoxicity to human brain-microvascular endothelial cells. The immunochemical staining revealed that the crosslinked anti-EGFR on the surface of Dox-CASLNs preserved a high specificity in recognizing EGFR on U87MG cells and inducing growth-inhibition effect. The innovated anti-EGFR/Dox-CASLNs can be an effective delivery system with high targeting efficacy against the growth of brain glioblastomas carcinoma.     

Optimization of Formulation and Process Variables for the Preparation of Novel Doxorubicin-Loaded Sonosensitive Nanodroplets

In the present study the effect of process (homogenization speed) and formulation (polymer concentration, surfactant concentration, drug amount, perfluorohexane volume fraction and co-surfactant inclusion) variables on particle size, entrapment efficiency, and drug release kinetics of doxorubicin-loaded alginate stabilized perfluorohexane nanodroplets were evaluated. Particle size and doxorubicin entrapment efficiency were highly affected by formulation and process variables. In vitro release profile of doxorubicin from all formulations was an apparently biphasic release process and 7–13 % of drug released from nanodroplets after 24 h incubation in PBS, pH 7.4, depending on the nanodroplets composition but ultrasound exposure for 10 min resulted in triggered release of 85.95 % of doxorubicin fromoptimal formulation (G). The inclusion of Span 60 (0.15 %), Poloxamer 188 (0.15 %) as co-surfactants reduced the particle size of nanodroplets from 51.8 to 42.3 and 35.6 nm, respectively. The entrapment efficiency decreased for span 60, while it did not changed in the case of Poloxamer 188. Comparison of drug release kinetics demonstrated that drug release was delayed for both Span 60 and Poloxamer 188. Thus, it was concluded that the particle size, entrapment efficiency and the doxorubicin release kinetics could easily be adjusted by taking advantage of process and formulation variables.     

Characterization of silver sulfadiazine-loaded solid lipid nanoparticles by thermal analysis

The aim of this study is the solid-state characterization of solid lipid nanoparticles (SLN) based on Compritol^® 888 (C888) and Lutrol^® F68 (F68), loaded with silver sulfadiazine (AgSD), used to develop sponge-like dressings to treat chronic skin ulcers such as decubitis and leg ulcers. Silver compounds like AgSD, in fact, are used to prevent and/or to treat wound colonization that could impair healing, also in the case of antibiotic-resistant bacteria. Thermal analysis, with support from powder X-ray diffractometry and Fourier transform infrared spectroscopy, is used to characterize lipid and drug bulk, unloaded and drug-loaded SLN. In particular, differential scanning calorimetry is used to investigate the degree of crystallinity and the solid-state modification of lipid, two parameters correlated to drug incorporation and drug release rates. The solid-state characterization demonstrates AgSD entrapment in C888 as a core enclosed into F68 shell. AgSD SLN are also stored at different temperatures 25 and 37 °C, respectively, to study the effect of storage conditions, that induce an increase of the lipid crystallinity index correlated to drug release from the lipid matrix.     

环丙沙星-聚羟基丁酸酯电纺纤维毡的制备、性质及抑菌活性研究

术后粘连是腹腔、妇科、矫形外科及心脏手术之后遇到的一个普遍的问题。大约80-90%的腹腔粘连直接起因于先前的手术[1]。这些粘连可以通过二次手术治疗,但这不仅耗时、花费高,而且增加了再次粘连、疤痕组织形成和细菌感染的潜在性。粘连的预防能减少医疗费用及治疗的复杂程度。     

Temperature scanning ultrasonic velocity study of complex thermal transformations in solid lipid nanoparticles

The purpose of this study was to determine whether temperature scanning ultrasonic velocity measurements could be used to monitor the complex thermal transitions that occur during the crystallization and melting of triglyceride solid lipid nanoparticles (SLNs). Ultrasonic velocity ( u) measurements were compared with differential scanning calorimetry (DSC) measurements on tripalmitin emulsions that were cooled (from 75 to 5 degrees C) and then heated (from 5 to 75 degrees C) at 0.3 degrees C min (-1). There was an excellent correspondence between the thermal transitions observed in deltaDelta u/delta T versus temperature curves determined by ultrasound and heat flow versus temperature curves determined by DSC. In particular, both techniques were sensitive to the complex melting behavior of the solidified tripalmitin, which was attributed to the dependence of the melting point of the SLNs on particle size. These studies suggest that temperature scanning ultrasonic velocity measurements may prove to be a useful alternative to conventional DSC techniques for monitoring phase transitions in colloidal systems.